During last 10 years the number of studies which devoted to using of medical physical factors in rehabilitation of patients with breast cancer has increased. Using any physical factor in rehabilitation should be proved by results of evidence-based studies.
The article presents data of scientometric analysis of 748 studies from 1980 till 2018 which were devoted to using of medical physical factors in rehabilitation of 261643 patients with breast cancer. The most studied physical factors with authentically proven effect are physical exercises, water based physical exercises, compression therapy. Process of synthesis and analysis of study results should be done regularly.

The review analyzes current data on the molecular mechanisms of resistance to monoclonal antibodies in patients with
squamous cell carcinoma of the tongue and mucosa of the oral cavity. The mechanisms of resistance to monoclonal anti-ERBB
and anti-PD1 antibodies and ways to overcome it are described in detail. The analysis made it possible to identify a number of factors
that should be taken into account when assigning therapy with monoclonal antibodies: activation of alternative receptor tyrosine
kinases, increased expression of receptor ligand genes, mutations in effectors and the receptor tyrosine kinases themselves, disruption
of the formation of functional receptor dimers, changes in proteins and coding for them genes responsible for the regulation of
cascades of apoptosis, mitosis, epithelial-mesenchymal transition, secretion of anti-inflammatory cytokines and immunosuppressive
metabolites.

Recently published results of CARMENA study seem to eliminate cytoreductive nephrectomy from current recommendations on the treatment of metastatic renal cell carcinoma patients who are candidates for targeted antiangiogenic therapy. The article is devoted to the critical analysis of the CARMENA trial and review of previously published data. Taking into account available data cytoreductive nephrectomy should be still performed in carefully selected patients.

The aim of this study was to evaluate the effect of the chemoradiation therapy on the incidence of postoperative complications and mortality rate in patients with locally advanced tumors of the thoracic esophagus.
The study included men and women over 18 with histologically verified squamous cell carcinoma of the thoracic esophagus with TNM stage cT3-4aN0-3M0. Patients were divided into two groups: patients in a main group (n=26) received a complex treatment, patients in a second group (n=30) undergoing only surgical treatment.
The first stage of treatment was performed for all 26 patients and included 2 courses of preoperative chemotherapy, followed by a chemoradiation therapy with a 44–46 Gy with weekly injections of chemotherapy. Surgical procedure (R0) was performed for 24 patients (92.3 %) in the main group and for 26 (86.6 %) in a second group.
Therapeutic complications were developed in 17 (65 %) patients in a first group, while in a second group this rate was in 18 (60 %) patients from 30. The incidence of surgical complications was slightly higher in a group of patients received a complex treatment –
7 (26.92 %) patients. In the surgical group such complications was  noted in 6 (20 %) patients. The only death in an early postoperative period was in 1 (3.84 %) patient from the main group. The cause was sepsis and the development of multiple organic failure. There were no lethal outcomes in a surgical group.
Estimating the incidence of complications, it should be noted that the use of chemoradiation therapy in the neoadjuvant regimen does not significantly affect the course of the postoperative period. The mortality rate was slightly higher in in the group of patients received complex treatment. At the same time, improvement of the ostoperative period and a reduction of mortality rate in group of
patients undergoing complex treatment is possible due to  optimization of preoperative preparation, postoperative management and competent selection of patients.

In this article, based on two clinical examples, the possibilities of multiparametric ultrasound in the differential diagnosis of metastatic and lymphoproliferative changes in lymph nodes in primary-multiple malignant tumors, including breast cancer and lym - phoma, are evaluated. Multiparameteric ultrasound includes B-mode, color and energy Doppler imaging, strain elastography, shear wave elastography and contrast-enhanced ultrasound (CEUS). Standardization and reproducibility of these ultrasound techniques will allow to objectify the study, obtaining specific indicators of shear wave velocity in the zones of interest and specific signs of contrast enhancement, which can be used as impor tant differential diagnostic tool in oncology.

An association of genes XRCC1 and HMMR with breast cancer (BC) has never been tested in the Kyrgyz ethnic group. This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 53 years (24–74, SE mean = 0.967, STD=9.81). The extraction of DNA was carried out from venous blood. The genotyping was conducted by using the method of polymerase chain reaction and restriction fragment length polymorphism. When comparing the results of genotyping, the histological structure of the tumor and the «menopause» factor, Fisher»s exact test was used. Calculation of the odds ratio was carried out by cross tabulation method. A statistically significant link between the XRCC1 Arg194Trp polymorphism and the menopausal status was observed (p=0,018). The Arg / Arg genotype of XRCC1 Arg194Trp polymorphism occurred in 52 % of cases in women at menopausal age, whereas in women before the onset of menopause, the genotype Arg / Arg occurred in 78.8 % of BC cases (p=0.009). The CT genotype of HMMR V353A polymorphism was identified as “protective” factor – OR=0.481, 95 % CI [0.27‑0.85]. There was no statistically significant association between the results of genotyping and histological structure of the tumor, as well as the age of verification of the diagnosis of BC.

The article briefly describes the mechanism of action of immunotherapeutic drugs that suppress the activity of “checkpoints” of the immune response CTLA-4 and PD-1. Modern methods of clinical efficacy and advantages of applying nivolumab, pembrolizumab and atezolizumab in colorectal cancer. The existing evidence base of the potential predictive and prognostic role of MSI status is summarized and presented information on the prospects for the further development of this therapeutical treatment of malignant tumors.